Literature DB >> 21925049

Endocrine hypertension--current understanding and comprehensive management review.

Norlela Sukor1.   

Abstract

Hypertension is a very common disease, leading to significant morbidity with reduction in quality of life. In addition to being a major cause of morbidity and mortality, hypertension places a heavy burden on health care systems, families, and society as a whole. In patients with hypertension, the ability to identify a contributing or secondary cause that is potentially curable or amenable to specific forms of management is of great importance. Endocrine hypertension has emerged as one of the common forms of secondary hypertension. Primary aldosteronism, pheochromocytoma and Cushing's syndrome are among the common causes of endocrine hypertension. The application of new clinical, biochemical, and radiologic approaches has significantly advanced our understanding of the pathophysiology and clinical spectrum of these diseases and improved the management strategies of these challenging conditions.
Copyright © 2011 European Feredation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21925049     DOI: 10.1016/j.ejim.2011.05.004

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  3 in total

Review 1.  Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea-what do we know so far?

Authors:  Huai Heng Loh; Norlela Sukor
Journal:  J Hum Hypertens       Date:  2019-12-10       Impact factor: 3.012

2.  [Etiology of endocrine arterial hypertensions: about a series of cases].

Authors:  Naima Bouznad; Ghizlane El Mghari; Nawal El Ansari
Journal:  Pan Afr Med J       Date:  2016-04-07

3.  Multimodality Imaging in Patients with Secondary Hypertension: With a Focus on Appropriate Imaging Approaches Depending on the Etiologies.

Authors:  Hyungwoo Ahn; Eun Ju Chun; Hak Jong Lee; Sung Il Hwang; Dong-Ju Choi; In-Ho Chae; Kyung Won Lee
Journal:  Korean J Radiol       Date:  2018-02-22       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.